Medytox filed a claim for termination of JV contract in China
This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology
김지선
stockmk2020@alphabiz.co.kr | 2023-01-20 08:36:30
[Alpha Biz=(Chicago) Reporter Paul Lee] Medytox announced on the 20th that GENTIX LIMITED has filed a claim for termination of the Chinese joint venture (JV) contract and compensation.
The applicant claimed compensation for damages equivalent to the applicant's damages, along with a claim to confirm the violation of the terms of the JV contract and to confirm that the applicant has the right to terminate the JV contract.
The amount of damages claims is 118.845 billion won, which is 29.45% of equity capital.
Medytox said, "We believe that there are no violations of the contract claimed by the other party, so we will actively respond through our legal representative."
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook
- 2Korean Air and LCC Affiliates Enter Emergency Management as Fuel Costs Surge Amid Middle East Conflict
- 3Amazon Web Services to Invest KRW 7 Trillion More in Korea by 2031, Expanding AI Infrastructure
- 4Lotte Group to Launch KRW 50 Trillion Real Estate Development Push to Tackle Liquidity Pressures
- 5Daesang Executive Arrested in KRW 10 Trillion Sweetener Price-Fixing Probe; CEOs Avoid Detention
- 6China Vanke Posts Record Loss as Property Slump Deepens Financial Strain